SB 11312
Latest Information Update: 09 Mar 2023
At a glance
- Originator Spring Bank Pharmaceuticals
- Developer F-star Therapeutics
- Class Antineoplastics; Nucleic acids; Small molecules
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (IV)